Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome

Neurobiol Aging. 2020 Sep:93:44-51. doi: 10.1016/j.neurobiolaging.2020.04.018. Epub 2020 Apr 29.

Abstract

Adults with Down syndrome have an increased risk for both disordered sleep and Alzheimer's disease (AD). In the general population, disrupted sleep has been linked to beta amyloid accumulation, an early pathophysiologic feature of AD. In this study, the association among sleep, beta amyloid, and measures of AD-related cognitive decline was examined in 47 non-demented adults with Down syndrome (aged 26-56 years). Sleep was measured using actigraphy over 7 nights. Pittsburgh Compound B positron emission tomography was used to assess global and striatal beta amyloid burden. Participants had the following clinical AD status: 7 (15%) mild cognitive impairment and 40 (85%) cognitively unaffected. Average length of night-time awakenings was significantly positively associated with striatal beta amyloid and decreased cognitive performance in executive functioning and motor planning and coordination. Findings suggest that disrupted sleep is associated with beta amyloid accumulation and cognitive features of preclinical AD in Down syndrome. Early identification and treatment of sleep problems could be a lifestyle intervention that may delay beta amyloid accumulation and cognitive decline in this AD vulnerable group.

Keywords: Alzheimer’s disease; Amyloid; Down syndrome; PET; Sleep.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Alzheimer Disease / etiology*
  • Alzheimer Disease / metabolism*
  • Amyloid beta-Peptides / metabolism*
  • Brain / diagnostic imaging
  • Brain / metabolism*
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / metabolism
  • Down Syndrome / complications*
  • Down Syndrome / metabolism*
  • Executive Function
  • Female
  • Humans
  • Male
  • Middle Aged
  • Positron-Emission Tomography
  • Sleep Wake Disorders / etiology*

Substances

  • Amyloid beta-Peptides